MapLight Therapeutics, Inc. filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission on November 16, 2026, covering up to $400,000,000 in securities including common stock, preferred stock, debt securities, and warrants.
Key Highlights
- Total shelf size: Up to $400,000,000 in aggregate offering price across common stock, preferred stock, debt securities, and warrants.
- ATM program included: Up to $100,000,000 of common stock may be sold from time to time under a sales agreement with Leerink Partners LLC, included within the $400,000,000 total.
- Stock price at filing: The last reported sale price of common stock on November 13, 2026 was $7.25 per share on The Nasdaq Global Select Market.
- Two share classes: The company has voting common stock and non-voting common stock; the registration covers voting common stock only unless otherwise noted.
- Company status: MapLight Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under applicable SEC definitions.
MapLight Therapeutics Registers Up to $400 Million in Mixed Securities
MapLight Therapeutics, Inc. (NASDAQ:MPLT), headquartered at 800 Chesapeake Drive, Redwood City, California, filed a Form S-3 shelf registration statement on November 16, 2026. According to the filing, the registration covers the potential offering, issuance, and sale of up to $400,000,000 in aggregate of common stock, preferred stock, debt securities, and warrants, to be offered "from time to time" on a continuous or delayed basis pursuant to Rule 415 under the Securities Act of 1933.
The filing discloses two distinct prospectus components within the registration statement. The base prospectus covers the full $400,000,000 across all security types, with specific terms of any individual offering to be detailed in a future prospectus supplement. A separate sales agreement prospectus covers up to $100,000,000 of common stock that may be sold under a sales agreement with Leerink Partners LLC. The filing states that the $100,000,000 available under the sales agreement prospectus is included within, and not in addition to, the $400,000,000 base prospectus amount. If shares are not sold under the sales agreement, that portion may be offered through other means under the base prospectus.
The company noted that securities may be sold directly to investors, through designated agents, or through underwriters or dealers. Fees, commissions, discounts, and net proceeds from any specific offering will be set forth in the applicable prospectus supplement. The registration statement had not yet been declared effective as of the filing date, and the prospectus itself states it "is not an offer to sell these securities." Christopher A. Kroeger, M.D. is identified as Chief Executive Officer and agent for service. The filing also notes that the company "may elect to comply with certain reduced public company reporting requirements" as an emerging growth company and smaller reporting company.
What Was Disclosed
MapLight Therapeutics filed a shelf registration seeking to offer up to $400,000,000 in mixed securities, including a $100,000,000 at-the-market component through Leerink Partners LLC, with specific offering terms to be provided in future prospectus supplements.




Please wait processing your request...